No, I still think the randomized, double-blinded, single-arm, 3 mg/kg arm will be very good. I still hope the first-line is good too, but this just reduces the overall impact. The package won't look as good now. The reality is that other drugs have failed against pancreatic cancer, like Avastin, but been approved for other indications.
News 
Market Data 
Discover 
